2009). Recent observations that galectins are increased after acute CNS injuries and during chronic neurodegeneration (Byrnes et al. 2006; Zhou et al. 2010) may support a potential role for galectins in the adaptive immune response to the “threat” of cell stress, damage,

or death, and potentially, in the repair function(s) of innate immunity (Kono and Rock 2008). Galectins contain a conserved carbohydrate recognition domain (CRD) with affinity for β-galactosides. They are secreted via a nonclassical pathway, but also found in intracellular compartments (Gong et al. 1999; Hughes 1999). Extracellularly, galectins form cross-links with cell surface glycoconjugates or Inhibitors,research,lifescience,medical the extracellular matrix, where they preferentially bind N-acetyllactosamine (Galß13GlcNAc or Galß1-4GlcNAC) residues. Because many cell surface receptors, including those for cytokines, growth factors, and neurotransmitters, contain glycoconjugates, galectins Inhibitors,research,lifescience,medical may modulate transmembrane signaling events that affect a variety of cell functions (Boscher et al. 2011). Recently, expression profiling revealed increases in mRNA for several galectins within

the spinal cord during late-stage selleckchem disease in mouse models of ALS (Ferraiuolo et al. 2007; Gonzalez de Aguilar et al. 2008; Zhou et al. 2010). Expression of galectin-3, also known as Mac-2, Inhibitors,research,lifescience,medical correlates with microglial activation subsequent to neuronal degeneration in mouse models of ALS (Yamanaka et al. 2008; Saxena et al., Inhibitors,research,lifescience,medical 2009; Hossiani et al. 2011), but nevertheless, its role in the disease is unclear. In this study, we initially assessed expression of multiple galectins, during chronic motor neuron disease in the SOD1G93A mouse and in patients with sporadic ALS. As galectin-3 was the only galectin to progressively increase from early to late stage of disease in the mouse, and was also confirmed in patients with sporadic ALS, we then focused on the Inhibitors,research,lifescience,medical role of galectin-3 in disease progression. Currently, available galectin-3 antagonists are carbohydrate based and are neither particularly selective,

nor able to cross the blood–brain barrier significantly (Pieters 2006). see more Therefore, we generated C57BL6 SOD1G93A/Gal-3−/− knock-out transgenic mice for our studies. Materials and Methods Animals Animal procedures were performed following National Institutes of Health Guidelines for Animal Use and Welfare and supported by an approved institutional animal protocol. B6SJL (stock no. 002726) or C57BL6 (stock no. 004435) mice with the G93A human SOD1 mutation (SOD1G93A; Gurney et al. 1994) were obtained from Jackson Laboratories (Bar Harbor, ME). For all studies, data were collected only from male mice, to avoid confounding issues of disease progression due to sex. The B6SJL strain was used for the expression studies.